Scholarlink

Rationale <p>MDMA (3–4 methylenedioxymethamphetamine) assisted psychotherapy has gained considerable attention as a potential adjuvant therapy for post-traumatic stress disorder (PTSD). Reports of the nonmedical use of MDMA suggest its adverse effects may include anxiety and anhedonia. However, the time course of these signs and symptoms and the potential alterations in neurotransmitter levels that may underlie these conditions are not well understood.</p> Methods <p>We subjected cohorts of male and female Sprague Dawley rats to MDMA (2.5 or 5&#xa0;mg/kg) or saline (1&#xa0;ml/kg), with each dose given three times at two-hour intervals. Anxiety-like behavior (open field test [OFT]/elevated plus maze [EPM]/light dark box [LDB] assays) was measured 1 and 15 days after MDMA. Anhedonia-related behavior (sucrose preference test [SPT]) was also measured for five successive days and at 15 days after MDMA. Finally, brains were isolated following behavioral testing and analyzed for monoamine levels in regions of interest.</p> Results <p>One day after exposure, the rats treated with repeated 2.5&#xa0;mg/kg (but not 5&#xa0;mg/kg) MDMA showed mild anxiety-like behavior in the OFT but this was confounded by reduced locomotion. Anxiety-like behavior was not affected 15 days after MDMA administration. Sucrose preference increased over time but was not impacted by treatment or sex. High-pressure liquid chromatography (HPLC) analysis revealed a significant reduction in serotonin levels in the nucleus accumbens, but not prefrontal cortex or dorsal hippocampus, of rats treated with 2.5 and 5&#xa0;mg/kg MDMA one day after exposure.</p> Conclusion <p>These findings indicate that mild effects following a one-day MDMA administration at the current doses (2.5 and 5&#xa0;mg/kg) may occur in both sexes, but these effects are transient. These data suggest that clinical use of MDMA at low doses may be tolerated and should not limit therapeutic usefulness.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A repeated low-dose regimen of MDMA has transient next-day effects on locomotor activity, anxiety-like behavior, and brain serotonin levels, with no effect on anhedonia-like behavior, in both female and male rats

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月4日

查看全文
  • Ava M. Mac,
  • Srinivasu Kallakuri,
  • Alixandria T. Mascarin,
  • Grant W. LeVasseur,
  • Saniya Haq,
  • Matthew M. Moua,
  • Abdul H. Vasiq,
  • Makayla E. Lewis-Gates,
  • Emily J. Thompson-Huber,
  • Matthew J. Baggott,
  • Shane A. Perrine

摘要

Rationale

MDMA (3–4 methylenedioxymethamphetamine) assisted psychotherapy has gained considerable attention as a potential adjuvant therapy for post-traumatic stress disorder (PTSD). Reports of the nonmedical use of MDMA suggest its adverse effects may include anxiety and anhedonia. However, the time course of these signs and symptoms and the potential alterations in neurotransmitter levels that may underlie these conditions are not well understood.

Methods

We subjected cohorts of male and female Sprague Dawley rats to MDMA (2.5 or 5 mg/kg) or saline (1 ml/kg), with each dose given three times at two-hour intervals. Anxiety-like behavior (open field test [OFT]/elevated plus maze [EPM]/light dark box [LDB] assays) was measured 1 and 15 days after MDMA. Anhedonia-related behavior (sucrose preference test [SPT]) was also measured for five successive days and at 15 days after MDMA. Finally, brains were isolated following behavioral testing and analyzed for monoamine levels in regions of interest.

Results

One day after exposure, the rats treated with repeated 2.5 mg/kg (but not 5 mg/kg) MDMA showed mild anxiety-like behavior in the OFT but this was confounded by reduced locomotion. Anxiety-like behavior was not affected 15 days after MDMA administration. Sucrose preference increased over time but was not impacted by treatment or sex. High-pressure liquid chromatography (HPLC) analysis revealed a significant reduction in serotonin levels in the nucleus accumbens, but not prefrontal cortex or dorsal hippocampus, of rats treated with 2.5 and 5 mg/kg MDMA one day after exposure.

Conclusion

These findings indicate that mild effects following a one-day MDMA administration at the current doses (2.5 and 5 mg/kg) may occur in both sexes, but these effects are transient. These data suggest that clinical use of MDMA at low doses may be tolerated and should not limit therapeutic usefulness.